Paroxysmal nocturnal hemoglobinuria: A classic description by Paul Strübing in 1882, and a bibliography of the disease
Crosby WH. Paroxysmal nocturnal hemoglobinuria: a classic description by Paul Strübing in 1882, and a bibliography of the disease. Blood 1951;6:270-284.
Effect of Eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
Hillmen P, Hall C, Marsh JC. Effect of Eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Eng J Med. 2004;350:552-559.
Effect of complement inhibitor Eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
Hillmen P, Muus P, Dührsen U. Effect of complement inhibitor Eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-4128.
Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)
Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003;11:102-110.
Cerebral Ischemic Infarction in Paroxysmal Nocturnal Hemoglobinuria. Report of 2 Cases and Updated Review of 7 Previously Published Patients
Audebert HJ, Planck J, Eisenburg M. Cerebral Ischemic Infarction in Paroxysmal Nocturnal Hemoglobinuria. Report of 2 Cases and Updated Review of 7 Previously Published Patients. J Neurol 2005;252:1379-1386.
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease
Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293:1653-1662.
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders
De Stefano V, Fiorini A, Rossi E. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Throm Haemost 2007;5:708-714.